

# Larynx and Base of Tongue 2024

NAACCR Monthly Webinar

October 3, 2024

## Case #1

71-year-old Caucasian male with history of hypertension, hyperlipidemia, diabetes mellitus, who presented with a four-week period of worsening dysphonia and hoarseness. Patient was a smoker until five years ago (1 PPD x 25 years). Social etoh (wine with dinner). Father diagnosed with prostate cancer at age 74.

On exam, no palpable masses or tenderness on neck. No palpable lymphadenopathy. Fiberoptic exam revealed a **left vocal cord white lesion**. No other lesions noted. Biopsy recommended.

### Imaging:

**3/25/24 @ ABC Hospital: CT Neck=** No definite true vocal cords, laryngeal or paralaryngeal lesions. No neck mass lesion or enlarged lymph nodes.

**3/28/24 @ ABC Hospital: PET/CT=** **FDG avid left true vocal cord mass extending to the anterior commissure**, SUV max 10.8. No other sites of abnormal FDG uptake.

### Pathology:

**4/3/24 @ ABC Hospital: Left true vocal cord biopsy=** **squamous cell carcinoma, moderately differentiated**.

### Treatment:

RT Completion Summary @ ABC Hospital:

Txt Site	Energy	Dose/fx	# of fx	Total dose (cGy)	Start date	End date
Glottis	6X/IMRT	2.25	28	6300	4/21/24	6/2/24

## CASE 1

Tumor Description		Grade				
Primary Site	C32.0	Clinical	2	Tumor Size Summary	999	
Laterality	0	Pathological	9			
Histology	8070	Post Therapy (yc)				
Behavior	3	Post Therapy (yp)				
AJCC Staging Items						
Clinical T	cT1a	Pathological T		ycT	ypT	
cT Suffix		pT Suffix		ycT Suffix	ypT Suffix	
Clinical N	cN0	Pathological N		ycN	ypN	
cN Suffix		pN Suffix		ycN Suffix	ypN Suffix	
Clinical M	cM0	Pathological M		yc M	ypM	
Stage Group	1	Stage Group	99	Stage Group	Stage Group	
SS2018/EOD						
Summary Stage 2018	1					
Extent of Disease						
EOD Primary Tumor	100	EOD Regional Nodes	000	EOD Mets	00	
Regional Nodes Positive	98					
Regional Nodes Examined	00					
SSDI						
ENE Clinical	7	LN Size of Mets	0.0			
ENE Pathological	X.9					
Surgery Codes			Systemic Therapy Codes			
Diagnostic Staging Procedure	02	Chemotherapy	00			
Surgical Procedure of Primary Site	A000	Hormone Therapy	00			
Scope of RLN Node Surgery	0	Immunotherapy	00			
Radiation						
Phase	1	2	3	1	2	3
Primary Treatment Volume	23	00		Dose Per fraction	225	
Draining LN	00			Fractions	028	
Modality	02			Total Dose	006300	
EB Planning Technique	05					

## Case #2

67-year-old female with h/o CKD, hypertension, hyperlipidemia, who presented to her primary care physician with a palpable right neck mass. Patients also report neck discomfort and swelling. Patient is a current 1PPD smoker. Negative family history. Social etoh (beer on weekends).

### Imaging:

1/8/24 @ XYZ Hospital: CT neck/soft tissue= Enlarged 3.0 cm right level IIA lymph node concerning for metastatic adenopathy. No other enlarged lymph nodes. No abnormal nodular or mass like enhancement within the visualized aerodigestive tract.

1/12/24 @ XYZ Hospital: PET/CT= FDG uptake co-registering with the enlarged RT level IIA lymph node (SUV max 20.2) noted on previous CT scan. Asymmetric FDG uptake at right root of tongue. No other sites of FDG uptake to suggest metastatic disease.

### Pathology:

1/15/24 @ XXX Hospital: FNA of right neck level II lymph node= metastatic squamous cell carcinoma.

HPV in situ hybridization: HPV low risk (6/11) negative. HPV high risk (16/18/33) positive.

EBER ISH probe negative.

P16 Patchy expression of p16 by immunohistochemistry.

### Treatment:

RT Completion Summary @ XXX Hospital:

Txt Site	Energy	Dose/fx	# of fx	Total dose (cGy)	Start date	End date
BOT/H&N	6X/Arc	200	35	7,000	2/1/24	3/20/24

2/1/24 @ XXX Hospital: Single agent cisplatin concurrent with EBRT.

**CASE 2**

Tumor Description		Grade			
Primary Site	C01.9	Clinical	9	Tumor Size Summary	999
Laterality	0	Pathological	9		
Histology	8085	Post Therapy (yc)			
Behavior	3	Post Therapy (yp)			
Schema Discriminator 2: Oropharyngeal p16			1-p16 negative		
<b>AJCC Staging Items (correct answer to scenario 2)</b>					
Clinical T	88	Pathological T	88	ycT	ypT
cT Suffix	88	pT Suffix	88	ycT Suffix	ypT Suffix
Clinical N	88	Pathological N	88	ycN	ypN
cN Suffix	8	pN Suffix	8	ycN Suffix	ypN Suffix
Clinical M	88	Pathological M	88	yc M	ypM
Stage Group	88	Stage Group	88	Stage Group	Stage Group
<b>SS2018/EOD</b>					
<b>3 Regional to Lymph Nodes</b>					
<b>Extent of Disease</b>					
999	EOD Regional Nodes	300	EOD Mets	00	
<b>AJCC Staging Items</b>					
<i>Changes to scenario above: 1.5 cm tumor confined to the base of the tongue and IHC test not done (histology 8086)</i>					
Clinical T	cT1	Pathological T		ycT	ypT
cT Suffix		pT Suffix		ycT Suffix	ypT Suffix
Clinical N	cN1	Pathological N		ycN	ypN
cN Suffix	(f)	pN Suffix		ycN Suffix	ypN Suffix
Clinical M	cM0	Pathological M		yc M	ypM
Stage Group	3	Stage Group		Stage Group	Stage Group
<b>SS2018/EOD</b>					
<b>3 Regional to Lymph Nodes</b>					
<b>Extent of Disease</b>					
EOD Primary Tumor	100	EOD Regional Nodes	300	EOD Mets	00
<b>AJCC Staging Items</b>					
<b>Changes to scenario above: 1.5 cm tumor confined to the base of the tongue p16+</b>					

<b>Clinical T</b>	cT1	<b>Pathological T</b>	88	<b>ycT</b>		<b>ypT</b>	
<b>cT Suffix</b>		<b>pT Suffix</b>	88	<b>ycT Suffix</b>		<b>ypT Suffix</b>	
<b>Clinical N</b>	cN1	<b>Pathological N</b>	88	<b>ycN</b>		<b>ypN</b>	
<b>cN Suffix</b>	(f)	<b>pN Suffix</b>	8	<b>ycN Suffix</b>		<b>ypN Suffix</b>	
<b>Clinical M</b>	cM0	<b>Pathological M</b>	88	<b>yc M</b>		<b>ypM</b>	
<b>Stage Group</b>	1	<b>Stage Group</b>	88	<b>Stage Group</b>		<b>Stage Group</b>	
<b>SS2018/EOD</b>							
<b>Summary Stage 2018</b>	3 Regional to Lymph Nodes						
<b>Extent of Disease</b>							
<b>EOD Primary Tumor</b>	100	<b>EOD Regional Nodes</b>	300	<b>EOD Mets</b>	00		
<b>Regional Nodes Positive</b>	95						
<b>Regional Nodes Examined</b>	95						
<b>SSDI</b>							
<b>ENE Clinical</b>	0	<b>LN Size of Mets</b>	30.0				
<b>ENE Pathological</b>	X.9	<b>SEER SSF 1</b>	71-HPV status reported in medical records as positive, but test type is unknown				
<b>Surgery Codes</b>				<b>Systemic Therapy Codes</b>			
<b>Diagnostic Staging Procedure</b>	00		<b>Chemotherapy</b>	02			
<b>Surgical Procedure of Primary Site</b>	00		<b>Hormone Therapy</b>	00			
<b>Scope of RLN Node Surgery</b>	1 Bx or aspiration		<b>Immunotherapy</b>	00			
<b>Radiation</b>							
<b>Phase</b>	1	2	3		1	2	3
<b>Primary Treatment Volume</b>	22	00		<b>Dose Per fraction</b>	00200		
<b>Draining LN</b>	01			<b>Fractions</b>	035		
<b>Modality</b>	02			<b>Total Dose</b>	007000		
<b>EB Planning Technique</b>	05						

### **Case #3**

69-year-old Caucasian male with h/o thyroid nodule, hypertension, GERD, who presented with a palpable “lump” at the angle of the jaw on the right side, with associated TMJ symptoms. Patient also reported intermittent difficulty with swallowing. Denies weight loss or SOB. Nonsmoker. No alcohol use. Father w/ non-melanoma skin cancer (BCC).

#### **Imaging:**

**3/28/24 @ XXX Hospital: CT Neck/soft tissue=** 1.5 cm lobulated enhancing RT base of tongue mass noted, consistent with neoplasm. Mass extends to the level of the vallecular. Bilateral cervical chain metastatic lymphadenopathy with prominent RT level II 1.9 cm nodal mass.

**4/5/24 @ XXX Hospital: PET/CT=** Abnormal hypermetabolic activity in RT tongue base mass (SUV max 20.1), consistent with biologic tumor activity. Conglomerate RT level II cervical lymph nodes (SUV max 21.2) and left cervical level II subcentimeter lymph nodes (SUV max 5.8). No other sites of abnormal FDG uptake.

#### **Pathology:**

**4/2/24 @ XXX Hospital: Right-sided neck level II lymph node US-guided FNA=** positive for malignant cells, necrotic neoplastic cells, consistent with metastatic squamous cell carcinoma.

Flow cytometry analysis non-contributory due to too few viables lymphocytes.

IHC stain for p16 strongly positive.

#### **Treatment:**

##### **RT Completion Summary @ YYY Hospital**

<b>Txt Site</b>	<b>Energy</b>	<b>Dose/fx</b>	<b># of fx</b>	<b>Total dose (cGy)</b>	<b>Start date</b>	<b>End date</b>
<b>Oropharynx/Neck</b>	6X/VMAT	200	35	7,000	4/24/24	6/19/24

**Cisplatin** administered concurrently with EBRT @ YYY Hospital.

## CASE 3

Tumor Description		Grade			
Primary Site	C01.9	Clinical	9	Tumor Size Summary	015
Laterality	0	Pathological	9		
Histology	8085	Post Therapy (yc)			
Behavior	3	Post Therapy (yp)			
AJCC Staging Items					
Clinical T	cT1	Pathological T		ycT	ypT
cT Suffix		pT Suffix		ycT Suffix	ypT Suffix
Clinical N	cN2	Pathological N		ycN	ypN
cN Suffix	f	pN Suffix		ycN Suffix	ypN Suffix
Clinical M	cM0	Pathological M		yc M	ypM
Stage Group	2	Stage Group	99	Stage Group	Stage Group
SS2018/EOD					
Summary Stage 2018	4-Regional by Direct Extension and Regional Lymph Nodes				
Extent of Disease					
EOD Primary Tumor	200	EOD Regional Nodes	400	EOD Mets	00

Regional Nodes Positive	95					
Regional Nodes Examined	95					
SSDI						
ENE Clinical	0	LN Size of Mets	19.0			
ENE Pathological	X.9	SEER SSF 1	11-HPV positive by p16 test			
Surgery Codes			Systemic Therapy Codes			
Diagnostic Staging Procedure	00	Chemotherapy	02			
Surgical Procedure of Primary Site	00	Hormone Therapy	00			
Scope of RLN Node Surgery	1	Immunotherapy	00			
Radiation						
Phase	1	2	3	1	2	3
Primary Treatment Volume	22			Dose Per fraction	200	
Draining LN	01			Fractions	035	
Modality	02			Total Dose	007000	
EB Planning Technique	05					